HomeMCPWorkbenchSkills
HomeWorkbenchNotificationsMe
llms.txt · MCP GuidePrivacy Policy · Terms of Service · Supportv1.8.3
  1. Home
  2. /Compound

Agomelatine

HCID 82148
New reaction
Print

Completing data — refresh the page later to see the latest

Basic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
Substructure searchFind similar structures

Basic information

CAS
138112-76-2
Standard SMILES
COc1ccc2cccc(CCNC(C)=O)c2c1
InChIKey
YJYPHIXNFHFHND-UHFFFAOYSA-N
Molecular formula
C15H17NO2
Average molar mass
243.3 g/mol
Monoisotopic mass
243.12592879

Overview

Agomelatine is a member of acetamides.

Names & identifiers

Preferred name
Agomelatine
IUPAC
N-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide
English name
Agomelatine
Molecular formula
C15H17NO2
Molecular weight
243.3

Names & synonyms

Agomelatine138112-76-2ThymanaxValdoxanS20098S-20098AgomelatinaAGO-178S 20098N-(2-(7-methoxy-1-naphthyl)ethyl)acetamideagomelatinumAGO178
Show more names
AGOMELATINGOMELATINEMELITORAgomelatine original crystal formomeLatineAgomeLMelitorCS-1963
DTXSID3057642137R1N49ADN-[2-(7-methoxy-1-naphthyl)ethyl]acetamideDTXCID4031431RefChem:110192N06AX22N-(2-(7-Methoxynaphthalen-1-yl)ethyl)acetamideN-[2-(7-methoxynaphthalen-1-yl)ethyl]acetamide

Database identifiers

CAS
138112-76-2
PubChem CID
82148
DTXSID
DTXSID3057642
ChEMBL
CHEMBL10878
ChEBI
CHEBI:134990
UNII
137R1N49AD
EC Number
629-727-7
Nikkaji
J481.046E

Properties

Computed structural propertiesFilling in

XLogP
2.7
Topological polar surface area
38.3 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
2
Rotatable bonds
4
Heavy atoms
18
Formal charge
0
Complexity
280

Experimental & physicochemical properties

Drugs · 3 items

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals

Pharmaceuticals -> Antidepressants

Solubility · 2 items

~0.5 mg/ml in 1:1 EtOH:PBS (pH 7.2); ~30 mg/ml in EtOH, DMF & DMSO

7.76e-03 g/L

Human Drugs · 2 items

Breast Feeding; Lactation; Milk, Human; Antidepressants

EMA approved medicines: Human medicine

Physical DescriptionSolid
Collision Cross Section156.3 Ų [M+H]+ [CCS Type: TW; Method: Major Mix IMS/Tof Calibration Kit (Waters)]

Physicochemical properties

Melting point
107 · 107-109°C
Boiling point
478.8 · 478.8±28.0 °C(Predicted)
Density
1.109 · 1.109±0.06 g/cm3(Predicted)
storage temp.

Safety & regulation

Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.

GHS classification

GHS Classification · 5 items

This chemical does not meet GHS hazard criteria for 1.9% (1 of 54) of reports.

Warning

H315 (22.2%): Causes skin irritation [Warning Skin corrosion/irritation]

P261, P264, P264+P265, P271, P273, P280, P302+P352, P304+P340, P305+P351+P338, P319, P321, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 54 reports by companies from 8 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Hazard information

Hazard Classes and CategoriesSkin Irrit. 2 (22.2%)

Toxicology

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

Safety data

wgk
3
rtecs
AC5956323
ridadr
UN 3077 9 / PGIII
hs_code
29241990
Toxicity
mouse,LD50,oral,> 1gm/kg (1000mg/kg),United States Patent Document. Vol. #5318994,
risk_code
50
Signal word
Warning
Symbol(GHS)
GHS09
hazard_code
N
safety_code

Chemistry & industry

Pharmacology

ATC Code · 3 items

N06AX22

N - Nervous system

QN - Nervous system

Protein Binding> 95%
Pharmacodynamics · 1 item

Agomelatine resynchronises circadian rhythms in animal models of delayed sleep phase syndrome and other circadian rhythm disruptions. It increases noradrenaline and dopamine release specifically in the frontal cortex and has no influence on the extracellular levels of serotonin. Agomelatine has shown an antidepressant-like effect in animal depression models, (learned helplessness test, despair test, and chronic mild stress) circadian rhythm desynchronisation, and in stress and anxiety models. In humans, agomelatine has positive phase shifting properties; it induces a phase advance of sleep, body temperature decline and melatonin onset. Controlled studies in humans have shown that agomelatine is as effective as the SSRI antidepressants paroxetine and sertraline in the treatment of major depression

Mechanism of ActionThe novel antidepressant agent, agomelatine, behaves as an agonist at melatonin receptors (MT1 and MT2) and as an antagonist at serotonin (5-HT)(2C) receptors.
Biological Half-Life<2 hours
Metabolism/MetabolitesHepatic (90% CYP1A2 and 10% CYP2C9).
MeSH Pharmacological ClassificationDrugs used to induce drowsiness or sleep or to reduce psychological excitement or anxiety.
Absorption, Distribution and ExcretionBioavailability is less than 5%.
Cellular LocationsMembrane

Uses & manufacturing

Related reactions

35 records
New reaction record
HRID 112654 reaction equation
HRID 112654As product
HRID 117375 reaction equation
HRID 117375As reactant
HRID 123320 reaction equation
HRID 123320As product
HRID 232780 reaction equation
HRID 232780As reactant
HRID 243636 reaction equation
HRID 243636As product
HRID 243637 reaction equation
HRID 243637As product
HRID 243638 reaction equation
HRID 243638As product
HRID 351136 reaction equation
HRID 351136As reactant
PreviousPage 1 of 5

Compound notes

On this pageBasic informationOverviewNames & identifiersPropertiesSafety & regulationChemistry & industryRelated reactionsCompound notes
2 · 2-8°C
solubility
50 mg/mL · DMSO: >50mg/mL
form
powder
pka
16.17 · 16.17±0.46(Predicted)
color
white to off-white
Merck
14 · 14,190
InChI
InChI=1S/C15H17NO2/c1-11(17)16-9-8-13-5-3-4-12-6-7-14(18-2)10-15(12)13/h3-7,10H,8-9H2,1-2H3,(H,16,17)
InChIKey
YJYPHIXNFHFHND-UHFFFAOYSA-N
SMILES
C(NCCC1=C2C(C=CC(OC)=C2)=CC=C1)(=O)C
CAS DataBase Reference
138112 · 138112-76-2(CAS DataBase Reference)
EWG's Food Scores
1 · 1
FDA UNII
137 R1N49AD · 137R1N49AD
ATC code
6 AX22 · N06AX22
UNSPSC Code
12352200 · 12352200
NACRES
77 · NA.77
Protein binding
95 % · 95%
Excreted unchanged in urine
Minimal (80% as inactive metabolites)
Volume of distribution
35 Litres · 35 Litres
Biological half-life
1 · 1-2
Symbol(GHS)
9 · GHS09
Signal word
Warning
Hazard statements
400 · H400
Precautionary statements
273 · P273
Hazard Codes
N
Risk Statements
50 · 50
Safety Statements
61 · 61
RIDADR
3077 · UN 3077 9 / PGIII
WGK Germany
3 · 3
RTECS
5956323 · AC5956323
HS Code
29241990 · 29241990
Storage Class
11 · 11 - Combustible Solids
Hazard Classifications
1 Aquatic · Aquatic Acute 1Aquatic Chronic 1
Toxicity
50 · mouse,LD50,oral,> 1gm/kg (1000mg/kg),United States Patent Document. Vol. #5318994,
61
Storage Class
11 - Combustible Solids
Hazard statements
H400
Hazard Classifications
Aquatic Acute 1Aquatic Chronic 1
Precautionary statements
P273
UsesUse (kg; approx.) in Germany (2009): >100
Applications · 5 items

UsesMelatonin drugs.

DescriptionAgomelatine is an agonist of melatonin (MT) receptors and a derivative of melatonin . It binds to MT1 and MT2 receptors (Kis = 0.14 and 0.41 nM, respectively) and has an EC50 value of 0.1 nM in a [35S]GTPγS binding assay using CHO cells expressing MT2 receptors. Agomelatine is also an antagonist of the serotonin (5-HT) receptor subtypes 5-HT2B and 5-HT2C (Kis = 0.26 and 0.71 nM, respectively, for the human receptors). Agomelatine (40 mg/kg) inhibits the penile erection response induced by the 5-HT2 agonist Ro 60-0175 in rats. It also increases extracellular levels of noradrenaline and dopamine in the frontal cortex of freely moving rats when administered at doses ranging from 20 to 80 mg/kg. Agomelatine (10 mg/kg) reduces immobility time in the forced swim test and increases the amount of time spent in the open arms of the elevated plus maze in mice, indicating antidepressant-like and anxiolytic-like activity, in a transgenic neuroendocrine model of depression. It also increases the rate of readjustment to circadian activity cycles following an induced phase shift.

UsesAgomelatine is a melatoninergic agonist and selective antagonist of 5-HT2C receptors, and has been shown to be active in several animal models of depression. Agomelatine (S20098) displayed pKi values of 6.4 and 6.2 at native (porcine) and cloned, human (h)5-hydroxytryptamine (5-HT)2C receptors, respectively.

UsesAgomelatine has been used: to study its effects on adult neurogenesis and hippocampus apoptosis using the stress-induced depression model of rats to explore its effects on tau protein phosphorylation and to study its neuroprotective mechanism to study its effects on intracellular calcium ([Ca2+]i) signaling in peripheral neurons of rat dorsal root ganglion (DRG) neurons

UsesAgomelatine is an antidepressant drug. It is classified as a norepinephrine-dopamine disinhibitor (NDDI) due to its antagonism of the 5-HT2C receptor. Activation of 5-HT2C receptors by serotonin inhibits dopamine and norepinephrine release. Antagonism of

Upstream & downstream products

Upstream raw materials

1384536-35-9185336-04-32-(7-Methoxy-1-naphthyl)ethylamine hydrochloride7-Methoxy-1-naphthylacetonitrileAgomelatine Impurity 12-(7-Methoxynaphthalen-1-yl)ethanamine2-(7-Methoxynaphthalen-1-yl)acetamide

Downstream products

N-acetyl-N-(2-(7-Methoxynaphthalen-1-yl)ethyl)acetaMide

Additional notes

DefinitionChEBI: Agomelatine is a member of acetamides.